Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With Previously Treated Advanced Non-small Cell Lung Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

26

Participants

Timeline

Start Date

December 2, 2012

Primary Completion Date

October 24, 2017

Study Completion Date

April 29, 2019

Conditions
Recurrent Non-Small Cell Lung CarcinomaStage IV Non-Small Cell Lung Cancer
Interventions
OTHER

Laboratory Biomarker Analysis

Correlative studies

DRUG

Paclitaxel Albumin-Stabilized Nanoparticle Formulation

Given IV

Trial Locations (12)

59715

Bozeman Deaconess Hospital, Bozeman

98052

Group Health Cooperative, Redmond

98109

Fred Hutch/University of Washington Cancer Consortium, Seattle

98274

Skagit Valley Hospital, Mount Vernon

98362

Olympic Medical Center, Port Angeles

98415

Multicare Health System, Tacoma

98801

Wenatchee Valley Hospital and Clinics, Wenatchee

99216

Spokane Valley Cancer Center-Mission, Spokane

99336

Kadlec Clinic Hematology and Oncology, Kennewick

99508

Anchorage Oncology Centre, Anchorage

Katmai Oncology Group, Anchorage

Providence Alaska Medical Center, Anchorage

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

collaborator

Celgene Corporation

INDUSTRY

lead

University of Washington

OTHER